GLP-1 Market
LLY $1181.89 ▲ +2.7% NVO $38.62 ▲ +1.2% PFE $28.41 ▲ +0.8% VKTX $36.75 ▼ -11.8% KLRA $11.98 ▼ -8.8% GPCR $36.02 ▲ +0.2% RHHBY $54.80 ▼ -0.5%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Dazucorilant

Company
Corcept Therapeutics
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 25, 2026

Trial details
  • Completed NCT NCT04249323

    Single and Multiple Ascending Dose Study of CORT113176 in Healthy Participants

    Not yet reported Corcept Therapeutics 110 participants Est. completion 2020-10-15 1 site Stand-alone
    Other conditions: Healthy Adults
    View official trial listing →
  • Completed NCT NCT04990310

    Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants

    Not yet reported Corcept Therapeutics 6 participants Est. completion 2021-09-20 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT04994743

    Safety, Tolerability, and Pharmacokinetic Study of CORT113176 in Healthy Participants

    Not yet reported Corcept Therapeutics 16 participants Est. completion 2021-09-30 1 site Stand-alone
    Other conditions: Healthy Adults
    View official trial listing →
  • Active, not recruiting NCT NCT05407324

    Dazucorilant in Patients With Amyotrophic Lateral Sclerosis

    Not yet reported Corcept Therapeutics 279 participants Est. completion 2027-11 35 sites Stand-alone
    Other conditions: Amyotrophic Lateral Sclerosis
    View official trial listing →
  • Completed NCT NCT06495944

    Impact of Itraconazole on the Pharmacokinetics and Safety of Dazucorilant in Healthy, Adult Participants

    Not yet reported Corcept Therapeutics 21 participants Est. completion 2024-08-02 1 site Stand-alone
    Other conditions: Healthy Adults
    View official trial listing →
  • Completed NCT NCT06928779

    Effects of Hepatic Impairment on the Pharmacokinetics of Dazucorilant

    Not yet reported Corcept Therapeutics 19 participants Est. completion 2024-12-09 2 sites Stand-alone
    Other conditions: Hepatic Impairment
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Dazucorilant, Dazucorilant 300 mg, CORT113176, Dazucorilant 150 mg

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.